Navigation Links
Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
Date:5/10/2011

e (CHF) and new onset CHF have been reported with TNF blockers.  Certolizumab pegol has not been formally studied in patients with CHF.  Exercise caution when using certolizumab pegol in patients who have heart failure and monitor them carefully.

Hypersensitivity

Symptoms compatible with hypersensitivity reactions, including angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria, have been reported rarely following certolizumab pegol administration.  If such reactions occur, discontinue further administration of certolizumab pegol and institute appropriate therapy.

Hepatitis B Reactivation

Use of TNF blockers, including certolizumab pegol, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. Some cases have been fatal.  Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating certolizumab pegol therapy.  Exercise caution in prescribing certolizumab pegol for patients identified as carriers of HBV, with careful evaluation and monitoring prior to and during treatment.  In patients who develop HBV reactivation, discontinue certolizumab pegol and initiate effective anti-viral therapy with appropriate supportive treatment.

Neurologic Reactions

Use of TNF blockers, including CIMZIA, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease, including multiple sclerosis, and with peripheral demyelinating disease, including Guillain-Barre syndrome. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA. Exercise caution in considering the use of CIMZIA in patients with these disorders.

Hematologic Reac
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
2. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
3. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
4. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
5. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
6. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
7. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
8. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
9. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
10. New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation
11. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... DIEGO , Oct. 20, 2014 ... industry leader in bioactive lipid-targeted therapeutics, received official notification ... has been granted another key patent supporting its ... newly issued patent, European patent No. 2087002, claims ... substance in Lpath,s two lead compounds, iSONEP and ...
(Date:10/20/2014)... Mary,s Medicinals today announced that its 501(c)(3) foundation, ... Operation Grow4Vets , a national, nonpartisan organization focused ... to assist them in living with injuries sustained while ... , An ever-increasing number of medical studies have shown ... pain, Post-traumatic Stress Disorder (PTSD) and Traumatic Brain Injury ...
(Date:10/20/2014)... N.C., Oct. 20, 2014  BioPontis Alliance for ... both philanthropies, announced today the creation of a ... treatment of the rare disease known as Charcot- ... its alliance model earlier this month. Today,s partnership ... a collaborative model where researchers and all CMT ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3
... On July 31 , Massachusetts lawmakers passed legislation ... sentencing laws. , , , ... Drug offenders serving mandatory minimum sentences at county Houses of Correction will ... bill lawmakers voted on did not include two reforms previously endorsed by ...
... Conatus Pharmaceuticals Inc. announced today that Conatus acquired the Idun Pharmaceuticals ... a privately-held drug development company focused on liver disease and oncology. ... Conatus Pharmaceuticals ... of Idun Pharmaceuticals, which was acquired by Pfizer Inc. in 2005.  "The ...
Cached Medicine Technology:FAMM Applauds Massachusetts Legislature for Sentencing Reforms 2Conatus Pharmaceuticals Acquires Pfizer's Idun Subsidiary 2
(Date:10/20/2014)... The Advocator Group, LLC is proud ... for Suicide Prevention’s (AFSP) Out of the Darkness walk ... that hosts hundreds of community walks throughout the country ... to help understand and prevent suicide through not only ... , The Advocator Group shares this passion for ...
(Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Principle Business ... takes pride in manufacturing top-of-the-line absorbent products. The ... of its most popular brand, Tranquility® Premium Protection absorbent ... a new website, gave its packaging a new look, ... the brand message to the public. , The new ...
(Date:10/20/2014)... October 20, 2014 Succeed is proud to ... companies who participated in the Every Body Walk! ... public awareness project that encourages workers to be more active ... 10,000 Program, which concluded at the end of September, was ... cities and metro areas. Participating companies gave their staff ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center ... hospital ROI on membership dues at 12.5. In other words, ... in value to member hospitals. The calculation used to determine ... , “This is the first time we’ve actually been ... methodology is really sound,” said Bill Ryan , president ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4
... highest risk, study finds , , TUESDAY, May 26 (HealthDay ... effects of alcohol, the greater your chance of becoming an alcoholic, ... sensitivity to imbibing intoxicants, called a low level of response (LR) ... get that buzz or other desired effect. The condition appears to ...
... Boston University School of Medicine (BUSM) and Boston University ... method fully resolves confounding by indication in observational studies, ... by unmeasured confounding, it is not straightforward to determine ... in obtaining a valid and precise estimate of effect. ...
... of East Asian and South Asian descent are between two ... at birth when compared to their Canadian counterparts, according to ... Ray. Dr. Ray and a team of researchers, who developed ... suggest the need to consider differences across ethnic groups to ...
... by researchers UT Southwestern Medical Center are accelerating efforts ... the world,s population. , The new findings, available online ... of the National Academy of Sciences, demonstrate that ... Caenorhabditis elegans, a common research worm, also provides the ...
... Washington, D.C. Tops List of America,s Fittest Cities SEATTLE, ... the fittest of America,s 50 most populous metropolitan areas ... American Fitness Index(TM) (AFI). ACSM unveiled the 2009 rankings ... Fitness Status of the 50 Largest Metropolitan Areas," during ...
... May 26 maxIT Healthcare LLC (maxIT), a ... the highest results in the staff augmentation category ... of the healthcare industry,s leading associations. According to ... published in February of 2009 by KLAS entitled ...
Cached Medicine News:Health News:Sensitivity to Alcohol May Predict Alcoholism 2Health News:BUSM researchers find no adjustment method fully resolves confounding by indication 2Health News:Newborns of South Asian and East Asian descent misclassified as underweight at birth: Study 2Health News:Researchers gain ground in efforts to fight parasite infection 2Health News:ACSM American Fitness Index(TM) Ranks 50 Largest Metro Areas on Health and Community Fitness 2Health News:ACSM American Fitness Index(TM) Ranks 50 Largest Metro Areas on Health and Community Fitness 3Health News:ACSM American Fitness Index(TM) Ranks 50 Largest Metro Areas on Health and Community Fitness 4Health News:ACSM American Fitness Index(TM) Ranks 50 Largest Metro Areas on Health and Community Fitness 5Health News:ACSM American Fitness Index(TM) Ranks 50 Largest Metro Areas on Health and Community Fitness 6Health News:ACSM American Fitness Index(TM) Ranks 50 Largest Metro Areas on Health and Community Fitness 7Health News:Is There a Meaningful Difference Between Healthcare IT Consulting Firms for Staff Augmentation? 2Health News:Is There a Meaningful Difference Between Healthcare IT Consulting Firms for Staff Augmentation? 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: